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Abstract We evaluated performance, accuracy, and
acceptability parameters of unsupervised oral fluid (OF)
HIV self-testing (HIVST) in a general population in
western Kenya. In a prospective validation design, we
enrolled 240 adults to perform rapid OF HIVST and
compared results to staff administered OF and rapid fin-
gerstick tests. All reactive, discrepant, and a proportion of
negative results were confirmed with lab ELISA. Twenty
participants were video-recorded conducting self-testing.
All participants completed a staff administered survey
before and after HIVST to assess attitudes towards OF
HIVST acceptability. HIV prevalence was 14.6 %. Thirty-
six of the 239 HIVSTs were invalid (15.1 %; 95 % CI
11.1–20.1 %), with males twice as likely to have invalid
results as females. HIVST sensitivity was 89.7 % (95 % CI
73–98 %) and specificity was 98 % (95 % CI 89–99 %).
Although sensitivity was somewhat lower than expected,
there is clear interest in, and high acceptability (94 %) of
OF HIV self-testing.
Keywords HIV  Self-testing  Oral fluid  Sensitivity 
Specificity
Introduction
Knowledge of HIV status is key to earlier access to HIV
treatment and prevention services. As an HIV prevention
strategy, HIV testing is cost effective, estimated to cost
US$249 per HIV-1 infection averted in Kenya [1, 2]. It is
also the fundamental entry point to an effective seek, test,
treat and retain (STTR) paradigm, which has the potential
to bend the curve of the HIV pandemic [3]. In resource
limited settings such as in sub-Saharan Africa, the shortage
of health care workers has been identified as a barrier in the
effort to scale up HIV prevention and treatment services.
Other barriers include stigma, health seeking behavior
among undiagnosed persons living with HIV (PLWH),
especially men, and an overemphasis on facility based
approaches to HIV testing services [4]. According to
population-based surveys in low- and middle-income
countries (LMIC), the median percentage of people living
with HIV who know their status is estimated at under 50 %
[5]. Given the public health implications of unknown HIV
status, especially among undiagnosed PLWH, the avail-
ability of self-testing for rapid scale up of HIV testing is
compelling [6]; increasing awareness of HIV status is an
important step towards reducing HIV transmission and
enabling antiretroviral therapy (ART) that reduces mor-
tality as well as secondary HIV transmission. HIV testing
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guidelines recently released by the World Health Organi-
zation (July 2015) highlighted the potential contribution of
HIV self-testing (HIVST) to close critical gaps in HIV
testing coverage, and to support retesting efforts, world-
wide [7].
Data from both blood and oral fluid HIV self-testing
studies conducted in Canada [8], China [9], Kenya [10],
Malawi [11], Singapore [12, 13], Spain [14, 15], South
Africa [16], Uganda [17], and the U.S. [18–21] show self-
testing is feasible, acceptable, and accurate. Availability of
self-testing is one of several options to increase access to
testing, especially in higher-risk subpopulations [9, 21] that
may not access current forms of HIV testing, such as HIV-
discordant couples, men who have sex with men (MSM),
sex workers (SWs), people who inject drugs (PWID), and
high-risk youth. Currently available options include vol-
untary counseling and testing (VCT), provider-initiated
counseling and testing (PICT), home-based counseling and
testing (HBCT), self-testing home specimen collection, and
mobile and outreach HIV testing and counseling. HIV self-
test results do not confer diagnosis, as a reactive (positive)
HIV self-test must be confirmed according to national
algorithms; individuals with non-reactive (negative) HIV
self-test results should be provided with information about
re-testing, especially if they had a recent exposure or are at
on-going risk. In the US, where approximately 1 in 5
people do not know they are infected [22], the Food and
Drug Administration (FDA) approved the OraQuick In-
Home HIV test kit, the first HIV self-test (HIVST) kit for
sale directly to consumers over-the-counter (OTC) and
online [19]. However, such an approach has not yet been
implemented as a standard option for non-health profes-
sionals in LMIC countries, e.g., sub-Saharan Africa, where
two-thirds of all HIV infection globally exists.
Kenya has been a leader in innovative approaches to HIV
prevention and care. The recent KAIS [23] national survey
found that levels ‘‘of HIV testing have increased with 72 %
of adults aged 15–64 years in 2012 reporting ever having
been tested for HIV, a significant increase from 34 % in
2007.’’ Ambitious population coverage targets for HIV
serostatus knowledge have been set, yet even with large-
scale HBCT programs, VCT scale up, and other approaches;
there still remains a coverage gap as noted by KAIS (one
that is larger for men than women). This suggests HIVST
has a place as part of a comprehensive testing strategy.
Kenya has successfully piloted HIVST among health
workers [10] and is the first African country (and one of the
first countries globally) to develop policy guidelines [24]
around HIVST for the general public. Our objective is to
evaluate the performance and accuracy parameters of
unsupervised oral fluid HIV self-testing among adult lay
users in the general population of Kenya. The study aims
were to determine (1) the ability of participants with
unknown HIV status to correctly perform and interpret a
rapid oral fluid (OF) HIV test and compare their results to
staff/lab testing (i.e., sensitivity and specificity measures)
and (2) participant attitudes and preferences towards OF
self-testing (i.e., OF HIVST acceptability and feasibility).
Methods
Participants
Study participants were recruited from three sites: a health
care facility that has expanded beyond HIV-only care
provision and two community workplace settings in
Eldoret, Kenya from November 11–29, 2013. Study flyers
with mobile phone contact numbers were used to recruit at
all three sites, along with provider word of mouth (clinical
site) and employer information with referral to our study
staff at the occupational sites. Eligibility criteria included
(1) adults (C18 years old), (2) who do not know their HIV
status because they have never tested or their last HIV test
was negative, and (3) live within 1 h of public transit travel
time to Eldoret town. Participants received 250 Kenyan
shillings (Ksh, equivalent to 3.00 USD) for their time and
to reimburse their transportation costs.
Study Procedures
We conducted a prospective validation study comparing
unsupervised self-administered OF HIVST among n = 240
individuals to staff-administered OF and rapid fingerstick
whole blood (FS) test; all reactive, discrepant, invalid, and
a proportion of the negative results were validated using an
enzyme-linked immunosorbent assay (ELISA). We also
assessed HIVST steps to understand errors in a subset of
the 240 participants, who agreed to be videotaped while
performing the steps of the self-testing. All participants
conducted an OF self-test, followed by staff administered
OF (to separate errors due to the lower accuracy of oral
specimens versus errors due to participants’ lack of
knowledge or experience with the self-testing kit [25] ) and
FS rapid diagnostic test. A subset of 20 participants’ self-
testing performance was video streamed which enabled
study staffers to monitor the steps, in a separate area, in real
time using a standardized checklist of steps and errors
noted [26]. Two study staff reviewed and compared their
checklists, and resolved discrepant observations. Only
participants enrolled from the health facility site were
asked to be part of the videotaped self-test usability com-
ponent of the study; every participant was invited at the
time of informed consent until 20 were enrolled.
The study was conducted over a single session and
enrollment was done with written informed consent of each
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participant. All study procedures were approved by Moi
University College of Health Sciences and Moi Teaching
and Referral Hospital’s Institutional Research and Ethics
Committee (#1029) and NYU’s University Committee on
Activities Involving Human Subjects (#13-9670). Follow-
ing informed consent, study staff administered a pre-
HIVST questionnaire to collect basic demographic infor-
mation and to assess risks, HIV test history, and HIV self-
testing importance, confidence, and concerns. Afterwards,
participants performed the self-testing in a private space,
using a pictorial instruction sheet with both English and
Kiswahili language text and icons, without supervision
from study staff members. The OraQuick ADVANCE
Rapid HIV 1/2 Antibody Test (OraSure Technologies), a
rapid diagnostic oral fluid test kit approved for use by the
Kenya Ministry of Health was used. After OF self-speci-
men collection, participants informed study staffer they
completed HIVST by interpreting their results aloud.
Afterwards, study staff administered a post-HIVST ques-
tionnaire to collect information about participant experi-
ence using the self-test kit, how HIVST should be
packaged or made available, possible reasons people may
or may not use HIV prevention and treatment services, as
well as some of the same information collected during the
pre-test questionnaire. Study staff then collected an OF
sample and a blood FS sample (The Alere Determine HIV-
1/2; Alere Medical Co.) and conducted parallel OF and FS
rapid HIV tests. A blood specimen was drawn for ELISA
confirmatory testing (Vironostika HIV Uni-Form II Ag/Ab;
bioMe´rieux Inc.) at the time of any reactive, discrepant, or
indeterminate/invalid OF/FS test results (except for one
participant with an invalid OF who refused) and a per-
centage (29 %) of OF negative results for quality control
purposes. The ELISA was selected as the reference stan-
dard as it is used in Kenya’s current national guidelines (at
the time of the study) as the final serostatus determination
assay and we followed these guidelines for the index
value/cutoff. A single laboratory staff person conducted
and read the ELISA who was trained to national standards
in the AMPATH lab, which ISO 15189:2007 certified.
Laboratory staff person was blinded to the results of the
other tests and did not have access to other clinical infor-
mation. Post-test counseling was provided according to
Kenya Ministry of Health guidelines, after completion of
all study procedures. All participants with a reactive test
result were notified of their confirmed HIV-positive status
once ELISA results were available and referrals/linkage to
appropriate HIV care were made.
Sample Size Determination
Assuming sensitivity is 96 % and specificity is 99 %, and
an undiagnosed HIV prevalence of 20 %, the total sample
size of up to N B 240 (minimum N = 180) provides
adequate (C80 %) power to detect key errors in HIV self-
testing steps during this usability/validation pilot, including
specimen collection and interpretation. For sensitivity, a
null hypothesis of Se = .80 can be rejected with 82 %
power when the true value is .96; for specificity, a null
hypothesis of Sp = .80 can be rejected with 99 % power
when the true value is .99.
For the videotaping we set out to attain a sample of 10
males and 10 females. Samples of this size have been
shown to have sufficient power to detect the large majority
of usability problems [27].
Statistical Analysis
Statistical analysis was conducted using Stata 13.1 (Stata
Corporation, College Station, Texas, USA). Distributions
of participants’ characteristics and OF HIVST, FS, and
ELISA laboratory results were assessed using contingency
tables. With ELISA and staff FS as gold standards, the
performance of the rapid OF HIVST diagnostic test was
estimated using the diagt module in Stata [28]. Cohen’s
kappa [29] also was reported in order to convey the
strength of agreement between different HIV diagnostic
tests.
Data from the observation checklist for videotaped
participants were entered into an excel database and data
were analyzed descriptively for common user errors.
Results
We enrolled a total of 240 participants. Figure 1 outlines
the status of enrollees. One study participant enrolled was
HIV-positive and diagnosed prior to the study; this indi-
vidual was removed from the analysis.
As seen in Table 1, the sample was approximately one
third female and two-thirds males. Most participants
(90 %) had tested for HIV, while 10 % (n = 23) reported
having never tested previously. A handful (n = 8 females,
3 %) said they had performed any kind of self-test before,
in this case an over the counter pregnancy test. Mean age
was 33, and mean education was 12 years. Two thirds of
the sample were laborers. Most participants (88 %) were in
a relationship, though we saw only six out of this group
who came in with a partner as part of a HIV-discordant
couple.
Sexual risk-taking was common (Table 1), with 81 %
acknowledging sex without a condom in the last month. Of
those with a main sex partner, two-thirds said their partners
had been tested for HIV, with 7 % of those reporting the
partner’s status was HIV-positive (8/9 of those were on
ART). Mean number of sex partners in the last month was
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1.35, indicating some possible sexual concurrency, a factor
thought to contribute to HIV epidemic spread. Around 6 %
of participants said they had traded sex for drugs, money,
food, clothing, shelter, or any other goods in the last
30 days. Almost half (45 %) said they were less concerned
about HIV than they used to be, though 91 % acknowl-
edged being ‘‘very worried about getting HIV; HIV stigma
was still prevalent (60 % ‘‘worried about what people in
the community will think if I have HIV’’) but not universal.
The majority had a previous history of HIV testing with
a mean of 3.77 tests taken (SD 2.30), and most had tested
within the last year (Table 2). Previous test sites included
VCT (61 %), with 31 % tested at a hospital and 4 % at
home. Reasons for not testing included fear and perceived
low risk. Concerns about testing HIV positive included
stigma, abandonment and violence (all over 50 %), with
confidentiality as the main/top reason for not having tested
for HIV before.
Prevalence of HIV infection was based on staff FS
results, since staff FS results were equivalent to the ELISA
laboratory blood test (sensitivity and specificity both
100 %) and available for all participants. A total of 35 of
239 participants were positive for HIV infection, indicating
prevalence of just under 15 % (14.6 %; 95 % CI
10.7–19.7 %).
Sensitivity and Specificity
Determination of the accuracy of OF HIV self-testing was
based on comparison with the ELISA blood test and staff
FS rapid HIV testing. Sensitivity was estimated as the
proportion of positive ELISA results that were also positive
by OF HIVST. Specificity was estimated as the proportion
of negative ELISA (or staff FS) results that were also
negative by OF HIVST. Among the 239 OF HIV self-
testing results, 36 (15.1 %; 95 % CI 11.1–20.1 %) were
invalid. More men than women had invalid tests; 7.7 %
(n = 6) women and 18.6 % (n = 30) men (p\ 0.03, OR
2.7). All individuals with an invalid test did recognize that
something had gone wrong with their test and did not
misinterpret it as either a negative or positive result. Given
that invalids thus represented a form of missing data, and in
order to document the most direct estimate of test perfor-
mance, we excluded invalid test results from analysis of
accuracy.
Table 3 compares positive test results by type of test; it
is worth noting that the fingerstick results were the same as
the lab-confirmed ELISAs in all cases where both were
available. Among 29 participants with positive ELISA
results, 3 false negatives were observed for OF HIVST
(Sensitivity = 89.7 %; 95 % CI 72.6–97.8 %). Among 49
250 Adults Assessed for Eligibility   
10 Were Not Enrolled 
   9 Did not meet inclusion criteria  
   1 Not interested in participating; 
takes too much time       
240 Adults Consented 
239 Enrolled 
                  1 Excluded, Screen fail 
Self-Administered OF Test Result 
      27 Positive 
      176 Negative 
36 Invalid
Staff-Administered OF Test Result 
      34 Positive 
      205 Negative 
Staff-Administered FS Test Result 
      35 Positive 
      204 Negative 
ELISA confirmed Positive 35 
113 ELISA confirmatory testing for any reactive, 
discrepant or indeterminate/invalid OF/FS test 
result and percentage of OF negative for QA 
Fig. 1 Enrollment
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participants with negative ELISA results, 1 false positive
was observed for OF HIVST (Specificity = 98.0 %; 95 %
CI 89.1–99.9 %). Among 29 participants with positive staff
FS results, 3 false negatives were observed for OF HIVST
(Sensitivity = 89.7 %; 95 % CI 72.6–97.8 %). Among 174
participants with negative staff FS results, one false posi-
tive was observed for OF HIVST (Specificity = 99.4 %;
95 % CI 96.8–99.9 %). All participants positive by FS
were confirmed by ELISA, which identified exactly the
same people as having HIV infection. However, only a
sample of negatives was confirmed by ELISA, hence the
slight difference in specificity. When the videotaped cohort
participants (n = 20) were excluded from analysis, OF
HIVST sensitivity was slightly higher (Sensitivity =
92.9 %; 95 % CI 76.5–99.1 %), and specificity slightly
lower (Specificity = 97.8; 95 % CI 88.5–99.9 %).
Negative and positive predictive values for OF HIVST
relative to ELISA and staff FS results were estimated as
well. Among 51 participants with a negative OF HIVST
result, 48 were also negative by ELISA (NPV = 94.1 %;
95 % CI 83.8–98.8 %). Among 27 participants with a
positive OF HIVST result, 26 were also positive by ELISA
(PPV = 96.3 %; CI 81.0–99.9 %). Among 176 partici-
pants with a negative OF HIVST result, 173 were also
negative by staff FS (NPV = 98.3 %; 95 % CI
95.1–99.6 %). Among 27 participants with a positive OF
HIVST result, 26 were also positive by staff FS
(PPV = 96.3 %; 95 % CI 81.0–99.9 %).
Cohen’s kappa was .89 (95 % CI .78–.99) for agree-
ment between OF HIVST and ELISA and was .92 (95 %
CI .84–.99) for agreement between OF HIVST and staff
FS results.











Age 30.86 (8.86) 40.38 (10.05) 36.74 (8.00) 35.96 (9.69)
Gender male 39 (50.65) 44 (60.27) 78 (87.64) 161 (67.36)
Highest education level 12.18 (3.86) 11.79 (2.66) 12.13 (2.77) 12.04 (3.13)
Relationship status
Single (no current main relationship) 14 (18.18) 2 (2.74) 13 (14.61) 29 (12.13)
Currently married (certificate/custom), one wife/husband 38 (49.35) 57 (78.08) 34 (38.20) 129 (53.98)
Currently in a relationship but not living with partner 18 (23.38) 4 (5.48) 1 (1.12) 23 (9.62)
Household monthly income
None 16 (21.05) 0 (0.00) 1 (1.12) 17 (7.14)
0–9999 Ksh 30 (39.47) 32 (43.84) 3 (3.37) 65 (27.31)
31)
C10,000 Ksh 30 (39.47) 41 (56.16) 85 (95.51) 156 (65.55)
Sexual Risk Behaviors
Sex without condom in last 12 months
Yes 58 (75.33) 61 (84.72) 73 (82.02) 192 (80.67)
One person consider as main sexual partner in past 30 days
Yes 60 (77.92) 63 (86.30) 77 (86.52) 200 (83.68)
Main partner ever tested for HIV
Yes 23 (38.33) 44 (69.84) 61 (79.22) 128 (64.00)
No 8 (13.33) 9 (14.29) 10 (12.99) 27 (13.50)
I don’t know 29 (48.33) 10 (15.87) 6 (7.79) 45 (22.50)
If yes, test results were: HIV results were positive 6 (26.09) 0 (0.00) 3 (4.92) 9 (7.03)
If positive, on ARVs? Yes 6 (100.00) N/A 2 (66.67) 8 (88.89)
Average number of sex partners, last mo (N = 23) 1.67 (0.58) 1.80 (0.84) 1.13 (0.35) 1.35 (0.57)
Traded sex for drugs, money, food, clothing, shelter, or any other goods in
the last 30 days
Yes 14 (18.18) 0 (0.00) 0 (0.00) 14 (5.86)
For age, highest education level, and average number of sex partners, cell contents are means with standard deviations in parentheses. For all
other variables, cell contents are count of participants with percentages in parentheses
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Test Performance Video Data
Twenty individuals were videotaped during their HIVST.
Video observation demonstrated that all participants
reviewed the instruction sheet prior to performing the self-
test. Problems noted covered a range of issues, some minor
(e.g., twisting rather than popping the cap, n = 14) and
others less so (e.g., placing swab in the buffer solution
before sample collection, n = 3). These errors are similar
to those that have been noted in a 3-country videotaped
HIVST study conducted by PATH [26]. In addition,
although not captured during the videotaping session, or
from the post-HIVST questionnaire, research assistant field
notes anecdotally describe one participant drinking the
buffer solution. Outcomes from the test performance video
data are summarized in Table 4. The same individual could
have made multiple errors.
Invalids
By design, samples positive by OF HIVST were over-
sampled for ELISA confirmatory testing, so it is not fea-
sible to use ELISA results to compare HIV prevalence
among participants with and without invalid OF HIVST
results. When staff finger-stick results (available for all
participants) are used as a gold standard for HIV infection,
those with invalid self-testing results had slightly increased
odds of infection, but the difference was not statistically
significant (OR = 1.20; p = 0.7977 by Fisher’s Exact
Test).
Table 2 Exposure to services, HIV test history, perceptions and concerns
Sites
Site 1 (n = 77) Site 2 (n = 73) Site 3 (n = 89) Overall (n = 239)
Ever tested for HIV
Yes 77 (100.00) 63 (86.30) 76 (85.39) 216 (90.38)
Number of times tested for HIV 3.55 (2.02) 2.48 (1.38) 5.04 (2.53) 3.77 (2.30)
How long ago was most recent test 10.81 (13.81) 17 .83 (17.16) 11.87 (26.04) 12.34 (20.42)
Most recent HIV test result
Positive 0 (0.00) 1 (1.59) 0 (0.00) 1 (0.46)
Negative 77 (100.00) 62 (98.41) 76 (100.00) 215 (99.54)
Didn’t get result 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Location where last tested for HIV
VCT 47 (61.04) 14 (22.22) 73 (96.05) 134 (62.04)
Clinical setting 30 (38.96) 40 (63.49) 2 (2.63) 72 (33.33)
Home 0 (0.00) 8 (12.70) 1 (1.32) 9 (4.17)
Other 0 (0.00) 1 (1.59) 0 (0.00) 1 (0.46)
If never tested, reasons why (check all that apply)
I thought I had a low chance of getting HIV 0 (0.00) 6 (60.00) 1 (7.69) 7 (30.43)
Takes too much time/inconvenient 0 (0.00) 1 (10.00) 4 (30.77) 5 (21.74)
I am afraid of knowing that I may have HIV 0 (0.00) 2 (20.00) 6 (75.00) 8 (33.33)
Other 0 (0.00) 1 (10.00) 3 (23.08) 4 (17.39)
Ever used self-tests in the past
Yes 7 (9.09) 1 (1.39) 0 (0.00) 8 (3.36)
No 70 (90.91) 71 (98.61) 89 (100.00) 230 (96.64)
Concerns about testing HIV positive (check all that apply)
Fear of stigma 73 (94.81) 42 (57.53) 41 (46.07) 156 (65.27)
Fear of abandonment 72 (93.51) 32 (43.84) 44 (49.44) 148 (61.93)
Fear of family violence 37 (48.05) 53 (72.60) 27 (30.34) 117 (48.95)
Confidentiality concerns 70 (90.91) 54 (73.97) 36 (40.45) 160 (66.95)
Access to treatment if you are HIV positive 11 (14.29) 65 (89.04) 9 (10.11) 85 (35.57)
Other 2 (2.60) 9 (12.33) 28 (31.46) 39 (16.32)
For number of times tested and time since the most recent test, cell contents are means with standard deviations in parentheses. For all other
variables, cell contents are count of participants with percentages in parentheses
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In our study sample, participants recruited from Site 3
had increased odds of an invalid test result (OR = 6.76;
p\ 0.0001 by Fisher’s Exact Test), and being male also
increased the odds of an invalid test result (OR = 2.74;
p = 0.0329 by Fisher’s Exact Test). Age ([25 years) and
education (\10 years) were not significantly associated
with the odds of an invalid OF HIVST result (OR = 2.13;
p = 0.3129 by Fisher’s Exact Test, and OR = 1.92;
p = 0.1179, by Fisher’s Exact Test, respectively). Partici-
pants who had never tested before had increased odds of an
invalid result, but this finding was only marginally signif-
icant (OR = 2.81; p = 0.0579 by Fisher’s Exact Test).
HIVST Acceptability
As seen in Table 5, results drawn from the post-HIVST
behavioral questionnaire closed-ended/quantified ques-
tions, the importance of having access to a HIVST increased
before vs. after the person conducted their own self-test,
Table 3 Results by type of test
Staff finger stick result Total
Negative Positive
Participant oral fluid self-test result
Invalida 30 6 36
Negative 173 3 176
Positive 1 26 27
Total 204 35 239
Staff oral fluid result
Invalida 0 0 0
Negative 204 1 205
Positive 0 34 34
Total 204 35 239
Excluding invalid results, three false negatives
(Sensitivity = 89.7 %)
Excluding invalid results, one false positive (Specificity = 98.0 %)
a Invalids were excluded due to being a form of missing diagnostic
data
Table 4 List of HIVST user
errors
Video observation user errors N
Test preparation
Difficulty opening packet 2
Difficulty opening bottle 14
Difficulty putting bottle in stand (holder)/Did not put bottle in stand 5
Placed stand in wrong position 2
Placed swab in stand 2
Placed swab on table 6
Sample collection
Did not swab between teeth and gums 1
Touched bottom of swab with fingers 2
Tongue touched swab 1
Holds swab in mouth 1
Used finger to swab with desiccant 1
Collected sample with finger instead of using swab 2
Placed swab in buffer solution before collecting sample 2
Placed swab in buffer solution without collecting sample 1
Placed finger in buffer solution before collecting sample with finger 1
General other errors
Added desiccant to solution 2
Used swab as stirrer 1
Spilled solution 2
Poured solution into stand 1
Spits into bottle 1
Illiteracy 2
Did not keep swab in bottle for the entire time 3
Timing
Waited\20 min to read results 13
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going from a mean of 8.1–8.6 (ascending scale 0–10).
Confidence in the ability to perform and interpret the self-
test appeared to increase with exposure to actually doing the
test. Confidence in doing the self-test correctly rose from
6.0 to 7.9 and ability to read results correctly from 6.1 to
8.1. Only 11 participants (4.6 % overall) thought that doing
the HIVST was ‘very difficult or difficult’ while 94 %
‘strongly agreed or agreed’ that HIVST was acceptable.
Affordability was a main theme in the behavioral survey
data, mentioned by n = 192/239. The mean price people
were willing to pay for a HIVST was 111 Ksh, around
US$1.25 (range 0–1000 Ksh). Female mean price was 78
Ksh and male mean was 158 Ksh, though median price was
50 Ksh for both. The mean price among those under age 25
was 56 Ksh and for those 25 and older was 120 Ksh. (Of
note, at the time of the study, the cost of the Oraquick self-
test kit was US$7.50 per kit or *600 Kenyan shillings at
an exchange rate of 80. However, the Oraquick test is not
yet publicly available for use in Kenya).
Discussion
This HIV self-test validation study conducted among a
general population sample of unsupervised lay users in
western Kenya found a sensitivity of 89.7–92.9 % and
specificity of 97.8–98.0 %. Agreement between OF HIVST
and both ELISA and staff FS results was very good. Of
note, around one in seven users had invalid results. The
study population had an overall HIV prevalence of just
under 15 %. By comparison, the KAIS 2012 national
household survey found HIV prevalence in the North Rift
Province where the study took place (Eldoret is in Uasin
Gishu County) was 3.1 %. The higher prevalence seen in
our sample as compared with that found in the province
during the KAIS 2012 survey suggests somewhat higher-
risk individuals self-selected to participate in the study,
which may be a selection bias but that at least indicates an
interest in HIVST among this epidemiologically and clin-
ically important subgroup of the general adult population.
Of note, 7.7 % (n = 6) women and 18.6 % (n = 30) of
the men had invalid HIVSTs. This may suggest less
familiarity with health tests among men. Potentially, fac-
tors such as literacy and previous exposure to health tests
may influence HIVST performance, perhaps suggesting the
need for educational campaigns and improved instructions
for the self-test kits, particularly for men who had an
invalid test rate more than double that of women.
Study limitations include the small sample size and
potential volunteer bias. Power to detect differences in
sensitivity or specificity based on participant characteristics
is low. The sample size for cases with infection is 29, and
for cases without infection is 49. Also, because the number
of diagnostic errors among those with a valid OF HIVST
result is very small (one false positive and three false
negatives), it is nearly impossible to identify statistically
significant predictors of diagnostic error/accuracy.
Supervised oral self-testing in Malawi found an overall
sensitivity of 97.9 % (95 % CI 87.9 %–100.0 %) and
specificity of 100 % (95 % CI 97.8 %–100.0 %) [11].
Although sensitivity in our study was lower than expected
in comparison, in the overall sample it was nearly 90 % for
unsupervised HIVST, similar to the 90 % reported for an
unsupervised HIVST study conducted in Uganda where
each participant first received a 10-minute HIVST
demonstration [17]. When the videotaped subjects were
Table 5 Pre and post HIVST importance, confidence, and acceptability
Sites
Site 1 (n = 77) Site 2 (n = 73) Site 3 (n = 89) Overall (n = 239)
Pre Post Pre Post Pre Post Pre Post






















































Think/feel using this test will be/wasa 2.60 0.00 5.48 0.00 5.62 12.36 4.60 4.60
Think/feel that HIV self-testing will be/is
acceptableb
100.00 100.00 100.00 100.00 87.64 84.27 95.40 94.14
a Responses have been dichotomized as percentage who said using HIVST was ‘very difficult or difficult’ (vs. ‘not difficult, easy, very easy’)
b Responses have been dichotomized as percentage who ‘strongly agreed or agreed’ HIVST was acceptable (vs. strongly disagree, disagreed, or
neither agreed or disagreed)
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excluded, sensitivity (92.9 %) was similar to that reported
to the Food and Drug Administration (phase 3, 92.9 %)
when they approved self-testing for general population use
in the US. In our study, positive predictive value at this
prevalence was reasonable at 96 %, though negative pre-
dictive value was lower at 94.1 %. Acceptability of HIVST
was high (94 %) and similar to what was found in studies
conducted in Malawi [11], Singapore [12], and the US [18].
In conclusion, there is clear interest in, and good accept-
ability of, HIV self-testing among the general population in
western Kenya that may help expand knowledge of
serostatus. Any rollout of HIVST should be accompanied
by education around appropriate use to reduce invalid
results and to encourage confirmatory testing and linkage
to HIV care where appropriate.
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